KB-1333

Mirvetuximab

Home » Antibody » Mirvetuximab

Background

Mirvetuximab represents a novel category of cancer therapy recognized as an antibody-drug conjugate. Its mode of action revolves around targeting folate receptor alpha (FR¦Á), a protein notably abundant on the surface of various cancer cells, notably ovarian cancer cells. Upon binding to FR¦Á, Mirvetuximab infiltrates the cancer cell, releasing a potent chemotherapy drug directly into its core. Subsequently, the administered drug induces cell death within the cancerous cells. This precise mechanism enables the delivery of concentrated chemotherapy doses specifically to cancer cells, thereby mitigating harm to healthy cells.

Specifications

Catalog Number:
KB-1333
Cell Line Name:
Mirvetuximab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
FOLR1
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1. Elahere demonstrates overall survival benefit in the phase 3 MIRASOL trial in patients with FR¦Á-positive platinum-resistant ovarian cancer. News release. ImmunoGen Inc. May 3, 2023. Accessed May 3, 2023. https://investor.immunogen.com/news-releases/news-release-details/elaherer-demonstrates-overall-survival-benefit-phase-3-mirasol. 2. ImmunoGen announces FDA accelerated approval of Elahere (mirvetuximab soravtansine-gynx) for the treatment of platinum-resistant ovarian cancer. News release. ImmunoGen Inc. November 14, 2022. Accessed May3,2023.https://investor.immunogen.com/news-releases/news-release-details/immunogen-announces-fda-accelerated-approval-elaheretm
Please enable JavaScript in your browser to complete this form.